Loss Of Tumor Suppressor Gene Triggers Colon Cancer

September 04, 1998

September 3,1998—Researchers have found the first connection between the loss of a tumor suppressor gene and activation of a cancer-promoting oncogene, a scenario thought to be prevalent in the initiation of many cancers but which has never been proven.

The newfound link also helps to explain the genesis of most cases of colon cancer, the second leading cause of cancer deaths in the United States.

The scientists found that mutated APC genes, regarded as one of the body's master brakes on cell growth, switch on c-MYC, a gene long associated with cancers of various sorts in both animals and humans.

"This connection is fascinating and we hope it leads to further understanding of this pathway," says Bert Vogelstein, an HHMI investigator at The Johns Hopkins Oncology Center. The report by Vogelstein and Johns Hopkins colleagues, Kenneth Kinzler and HHMI associate Tong-Chuan He, appears in the September 4, 1998, issue of the journal Science.

For Vogelstein, who has studied the genetic basis of colon cancer for nearly 20 years, "this ends one chapter of the APC story," but begins many more. "Master genes such as p53, another tumor suppressor, or APC usually don't work on just one pathway. So c-MYC is probably not the only gene whose expression is controlled by APC. We are working to find the others," he said.

The discovery also offers hope of finding new ways to treat colon cancer. Knowing that the c-MYC oncogene is one final link in the colon cancer chain "brings up an obvious and potentially powerful way to disrupt that interaction," Vogelstein says. Vogelstein's team plans to begin screening compounds that can block expression of the c-MYC oncogene through interference with the transcription factors regulated by APC.

In 1991, investigators including the Vogelstein-Kinzler team first identified APC (adenomatous polyposis coli), and linked mutations in that gene to colon cancer. Mutations in the APC gene were found in the hundreds of polyps that populate the colons of patients with an inherited disease, familial adenomatous polyposis (FAP). Similar mutations were found in about 85 percent of all colon cancers, including patients who had no family history of colon cancer.

By 1993, the researchers showed that APC interacts with the protein ß-catenin, a cell adhesion molecule commonly found in stomach tissue. That finding later helped to explain why nearly 10 percent of colon cancer cases develop with normal APC genes; the mutations are in ß-catenin.

Next it was shown that ß-catenin associates with the TCF family of proteins that activates gene transcription, and that APC regulates this association. This led to the hypothesis that APC, ß-catenin and Tcf-4 collaborate to regulate gene activity in colon cells, although the precise targets of that complex remained unknown. Finding those targets might tell the researchers how the protein complex promotes errant cell growth.

The break came when the team used a powerful screening procedure to sort out the genes that are turned on or off by APC. They found that the c-MYC gene quickly shut down after APC was applied, giving them direct evidence linking APC to c-MYC, a known oncogene.

Summarizing the results, Vogelstein explains that normal APC prevents ß-catenin from binding to Tcf-4, which, in turn, foils c-MYC expression. If APC or ß-catenin is mutated, however, the c-MYC oncogene is unchecked and promotes cell growth.

While Vogelstein says it is too early to speculate whether this pathway may be shared by a number of other cancers, he notes that "c-MYC is a powerful growth promoter, and this study should stimulate a lot of new work in this area." Under a licensing agreement between the Johns Hopkins University (JHU) and Genzyme, SAGE technology, which was used in this study, is licensed to Genzyme for commercial purposes. Kenneth W. Kinzler and Bert Vogelstein are entitled to a share of the royalty received by JHU from sales of the licensed technology.The SAGE technology is freely available to academia for research purposes. Kinzler and Vogelstein are consultants to Genzyme. JHU and the researchers own Genzyme stock, which is subject to certain restrictions under JHU policy. The terms of this arrangement are being managed by JHU in accordance with its conflict of interest policies.
-end-


Howard Hughes Medical Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.